Barton Haynes

Q: What Schools Are Affiliated With Barton Haynes

Barton Haynes is affiliated with the following schools: Simon Fraser University, University of Cape Town, Albert Einstein College of Medicine, Baylor College of Medicine, Duke University, Harvard University, University of Arkansas

Barton Haynes's AcademicInfluence.com Rankings

Barton Haynes

Philosophy

#2463

World Rank

#4203

Historical Rank

#873

USA Rank

Logic

#598

World Rank

#1070

Historical Rank

#230

USA Rank

philosophy Degrees

Download Badge

Philosophy

Barton Haynes's Degrees

Doctorate Medicine University of Arkansas

Why Is Barton Haynes Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Barton Ford Haynes is an American physician and immunologist internationally recognized for work in T-cell immunology, retrovirology, and HIV vaccine development. Haynes is a Frederic M. Hanes Professor of Medicine and Immunology at Duke University Medical Center. He is the director of the Duke Human Vaccine Institute and the Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery , which was funded by the National Institute of Allergy and Infectious Diseases in 2012. In addition, Haynes directs the B-cell Lineage Envelope Design Study, the Centralized Envelope Phase I Study, and the Role of IgA in HIV-1 Protection Study as part of the Collaboration for AIDS Vaccine Discovery , which was funded by the Bill and Melinda Gates Foundation in 2006.

(See a Problem?)

Barton Haynes's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. (1984) (3532)
Changes in thymic function with age and during the treatment of HIV infection (1998) (1921)
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. (1983) (1920)
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection (2008) (1911)
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. (2012) (1506)
A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 (2007) (1258)
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. (1978) (1091)
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus (2013) (940)
The immune response during acute HIV-1 infection: clues for vaccine development (2009) (884)
Diversity Considerations in HIV-1 Vaccine Selection (2002) (849)
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 (2011) (827)
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody (2012) (804)
A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. (1996) (788)
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection (2009) (781)
Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies (2005) (741)
Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing (2011) (730)
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection (2009) (690)
Leukocyte Typing II (1986) (687)
Structure and immune recognition of trimeric prefusion HIV-1 Env (2014) (682)
Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing (2008) (624)
Zika virus protection by a single low dose nucleoside modified mRNA vaccination (2017) (624)
Acute HIV-1 Infection. (2011) (615)
Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia (2008) (610)
CD44--a molecule involved in leukocyte adherence and T-cell activation. (1989) (570)
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. (1988) (521)
The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. (2000) (505)
Cyclophosphamide therapy of severe systemic necrotizing vasculitis. (1979) (455)
HIV‐1 neutralizing antibodies: understanding nature's pathways (2013) (455)
Toward an Understanding of the Correlates of Protective Immunity to HIV Infection (1996) (453)
Common Genetic Variation and the Control of HIV-1 in Humans (2009) (448)
B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study (2012) (439)
Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. (1981) (433)
Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors (2011) (420)
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants (2007) (419)
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface (2014) (416)
Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination (2014) (402)
Phenotypic properties of transmitted founder HIV-1 (2013) (389)
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. (2013) (381)
Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family (2012) (374)
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin (2011) (370)
Phenotypic characterization of cutaneous T-cell lymphoma. Use of monoclonal antibodies to compare with other malignant T cells. (1981) (350)
Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. (1980) (339)
The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. (1989) (337)
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1 (2009) (332)
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men (2010) (329)
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG (2013) (328)
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers (2009) (328)
Immunoregulatory aberrations in systemic lupus erythematosus. (1978) (320)
Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages (2011) (313)
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. (2013) (308)
Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing (2010) (297)
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization (2020) (296)
Induction of immunity to human immunodeficiency virus type-1 by vaccination. (2010) (293)
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses (2018) (292)
Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials (2012) (283)
The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature. (1977) (283)
Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. (2016) (276)
Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. (1989) (275)
Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years. (1982) (274)
Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants (2009) (270)
Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 (2013) (267)
A Critical Role for CD8 T Cells in a Nonhuman Primate Model of Tuberculosis (2009) (263)
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors (2015) (260)
Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies (2014) (259)
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody (2016) (259)
The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes1 (2007) (256)
Early events in human T cell ontogeny. Phenotypic characterization and immunohistologic localization of T cell precursors in early human fetal tissues [published erratum appears in J Exp Med 1989 Feb 1;169(2):603] (1988) (255)
Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection (2014) (253)
Transplantation of thymus tissue in complete DiGeorge syndrome. (1999) (252)
Role of HIV membrane in neutralization by two broadly neutralizing antibodies (2009) (250)
Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo (2014) (243)
Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 (2011) (240)
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. (2009) (233)
The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. (1991) (233)
Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. (1990) (231)
Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial (2013) (226)
Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity (2013) (225)
Wide Variation in the Multiplicity of HIV-1 Infection among Injection Drug Users (2010) (220)
An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum (2011) (218)
Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. (1981) (217)
Controlling the SARS-CoV-2 spike glycoprotein conformation (2020) (217)
Ontogeny of T-cell precursors: a model for the initial stages of human T-cell development. (1989) (216)
Analysis of the human thymic perivascular space during aging. (1999) (216)
Increased circulating Ia-antigen-bearing T cells in type I diabetes mellitus. (1982) (216)
Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. (2014) (214)
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines (2021) (207)
Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. (2010) (207)
Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants (2009) (207)
D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction (2020) (206)
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated (2011) (205)
Controlling the SARS-CoV-2 Spike Glycoprotein Conformation (2020) (205)
Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. (2000) (205)
Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein (2005) (205)
T cell receptor excision circle assessment of thymopoiesis in aging mice. (2002) (202)
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice (2020) (201)
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody (2012) (201)
Thymocyte binding to human thymic epithelial cells is inhibited by monoclonal antibodies to CD-2 and LFA-3 antigens. (1987) (200)
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. (2012) (200)
Latency reversal and viral clearance to cure HIV-1 (2016) (199)
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. (2006) (197)
Association of the human type C retrovirus with a subset of adult T-cell cancers. (1983) (197)
High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responses (2011) (197)
Leukemia Inhibitory Factor, Oncostatin M, IL-6, and Stem Cell Factor mRNA Expression in Human Thymus Increases with Age and Is Associated with Thymic Atrophy1 (2000) (195)
Human T Lymphocyte Antigens as Defined by Monoclonal Antibodies (1981) (195)
HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC (2009) (192)
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. (2012) (192)
The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes. (1978) (191)
Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals (2011) (190)
Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape (2012) (188)
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency (2015) (187)
Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors (2009) (186)
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines (2021) (184)
Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. (1989) (184)
Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance (2009) (181)
Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies (2015) (179)
The BB Diabetic Rat: Profound T-Cell Lymphocytopenia (1981) (179)
Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies (2017) (176)
Immune correlates of vaccine protection against HIV-1 acquisition (2015) (175)
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies (2021) (175)
The human thymic microenvironment. (1984) (175)
Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques (2016) (174)
Antibody polyspecificity and neutralization of HIV-1: a hypothesis. (2006) (174)
Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection (2009) (173)
Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires (2016) (173)
Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial (2013) (173)
Prospects for a safe COVID-19 vaccine (2020) (173)
Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets. (1979) (173)
The Characterization of Twenty Sequenced Human Genomes (2010) (171)
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies (2013) (171)
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation and antigenicity (2021) (170)
Enhanced: The Need for a Global HIV Vaccine Enterprise (2003) (168)
Monoclonal antibodies against the CD44 [In(Lu)-related p80], and Pgp-1 antigens in man recognize the Hermes class of lymphocyte homing receptors. (1989) (168)
HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities (2014) (167)
Characterization of a monoclonal antibody that defines an immunoregulatory T cell subset for immunoglobulin synthesis in humans. (1980) (167)
CD7+, CD4-, CD8- acute leukemia: a syndrome of malignant pluripotent lymphohematopoietic cells. (1989) (166)
Mosaic Vaccines Elicit CD8+ T lymphocyte Responses in Monkeys that Confer Enhanced Immune Coverage of Diverse HIV Strains (2010) (163)
Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design (2012) (161)
Early human T cell development: analysis of the human thymus at the time of initial entry of hematopoietic stem cells into the fetal thymic microenvironment (1995) (160)
H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination (2011) (159)
Copy Number Variation of KIR Genes Influences HIV-1 Control (2011) (158)
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates (2006) (157)
HIV-1-specific antibody responses during acute and chronic HIV-1 infection (2009) (157)
Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin. (1984) (156)
Mechanisms of corticosteroid action on lymphocyte subpopulations. IV. Effects of in vitro hydrocortisone on naturally occuring and mitogen-induced suppressor cells in man. (1979) (155)
CD6-ligand interactions: a paradigm for SRCR domain function? (1997) (155)
Phenotypic characterization and ontogeny of mesodermal-derived and endocrine epithelial components of the human thymic microenvironment (1984) (155)
Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting (2011) (155)
Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells (1995) (154)
Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7 (2012) (154)
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses (2021) (152)
Production of monoclonal antibodies reacting with peripheral blood mononuclear cell surface differentiation antigens. (1980) (152)
Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design (2015) (152)
Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. (2017) (148)
Phenotypic and Immunologic Comparison of Clade B Transmitted/Founder and Chronic HIV-1 Envelope Glycoproteins (2011) (146)
Polyreactivity and Autoreactivity among HIV-1 Antibodies (2014) (145)
T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces (2009) (144)
Viral Receptor-Binding Site Antibodies with Diverse Germline Origins (2015) (144)
Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. (2008) (141)
Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite (2018) (140)
Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections (2011) (139)
Mining the antibodyome for HIV-1–neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains (2013) (139)
Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination (2010) (138)
Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. (2003) (135)
Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development (2017) (133)
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques (2015) (133)
The human thymus during aging (2000) (133)
T-Cell recovery in adults and children following umbilical cord blood transplantation. (2001) (132)
Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection (2007) (131)
HIV-Host Interactions: Implications for Vaccine Design. (2016) (129)
The Development of CD4 Binding Site Antibodies during HIV-1 Infection (2012) (129)
Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. (2015) (129)
Human thymic epithelial cells produce interleukin 1. (1987) (128)
Identification of human and rodent thymic epithelium using tetanus toxin and monoclonal antibody A2B5. (1983) (127)
Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. (1989) (126)
Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys (2010) (125)
Phenotypic characterization of skin-infiltrating T cells in cutaneous T-cell lymphoma: comparison with benign cutaneous T-cell infiltrates. (1982) (122)
Evidence for susceptibility of intrathymic T-cell precursors and their progeny carrying T-cell antigen receptor phenotypes TCR alpha beta + and TCR gamma delta + to human immunodeficiency virus infection: a mechanism for CD4+ (T4) lymphocyte depletion. (1990) (122)
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity (2021) (121)
Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness (2017) (119)
Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design (2013) (119)
Thy1+ Nk Cells from Vaccinia Virus-Primed Mice Confer Protection against Vaccinia Virus Challenge in the Absence of Adaptive Lymphocytes (2011) (118)
Progress in HIV-1 vaccine development. (2014) (118)
Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis. (1983) (117)
Characterization of Glycosylation Profiles of HIV-1 Transmitted/Founder Envelopes by Mass Spectrometry (2011) (117)
Human T cell antigen expression by primate T cells. (1982) (116)
Cytokine Requirements for Induction of Systemic and Mucosal CTL After Nasal Immunization1 (2001) (116)
Human T cell antigen expression during the early stages of fetal thymic maturation. (1985) (116)
Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. (2014) (115)
Cytokine induction of the ability of human monocyte CD44 to bind hyaluronan is mediated primarily by TNF-alpha and is inhibited by IL-4 and IL-13. (1997) (115)
Activation of human B lymphocytes. III. Concanavalin A-induced generation of suppressor cells of the plaque-forming cell response of normal human B lymphocytes. (1977) (113)
Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection (2011) (113)
Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene. (1983) (113)
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge (2017) (111)
Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. (1989) (109)
In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth (2009) (108)
Multiple roles for HIV broadly neutralizing antibodies (2019) (108)
Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. (2013) (108)
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. (2015) (108)
Human thymic epithelial cells produce IL-6, granulocyte-monocyte-CSF, and leukemia inhibitory factor. (1990) (108)
Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV (2018) (108)
Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. (2011) (107)
CD4 mimetics sensitize HIV-1-infected cells to ADCC (2015) (107)
Emergence of suppressor cells of immunoglobulin synthesis during acute Epstein-Barr virus-induced infectious mononucleosis. (1979) (106)
Regulation of cytokine production in the human thymus: epidermal growth factor and transforming growth factor alpha regulate mRNA levels of interleukin 1 alpha (IL-1 alpha), IL-1 beta, and IL-6 in human thymic epithelial cells at a post-transcriptional level (1991) (106)
Ancestral and consensus envelope immunogens for HIV-1 subtype C. (2006) (106)
Monoclonal antibody against human T cell leukemia virus p19 defines a human thymic epithelial antigen acquired during ontogeny (1983) (105)
Potent and broad HIV-neutralizing antibodies in memory B cells and plasma (2017) (101)
Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses (2016) (101)
Immature human thymocytes can be driven to differentiate into nonlymphoid lineages by cytokines from thymic epithelial cells. (1989) (100)
Cell lines producing human T-cell lymphoma virus show altered HLA expression (1983) (100)
Scientific and social issues of human immunodeficiency virus vaccine development. (1993) (99)
Successful treatment of sudden hearing loss in Cogan's syndrome with corticosteroids. (1981) (99)
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. (2014) (99)
Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization (2002) (99)
Leptin Selectively Augments Thymopoiesis in Leptin Deficiency and Lipopolysaccharide-Induced Thymic Atrophy1 (2006) (99)
Effect of Thymectomy on Human Peripheral Blood T Cell Pools in Myasthenia Gravis (2001) (98)
In vitro culture of human peripheral blood monocytes induces hyaluronan binding and up-regulates monocyte variant CD44 isoform expression. (1996) (97)
Successful engraftment of human postnatal thymus in severe combined immune deficient (SCID) mice: differential engraftment of thymic components with irradiation versus anti-asialo GM-1 immunosuppressive regimens (1991) (97)
HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. (2014) (96)
Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission: Implications for HIV-1 Vaccine Design (2008) (96)
Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. (2009) (96)
Rescue of HIV-1 Broad Neutralizing Antibody-Expressing B Cells in 2F5 VH × VL Knockin Mice Reveals Multiple Tolerance Controls (2011) (96)
Immunoglobulin and T-cell receptor gene rearrangement and expression in human lymphoid leukemia cells at different stages of maturation. (1986) (96)
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice (2021) (95)
Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies (2011) (94)
The human thymic microenvironment: thymic epithelium contains specific keratins associated with early and late stages of epidermal keratinocyte maturation. (1986) (94)
Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation (2014) (93)
Immune perturbations in HIV-1–infected individuals who make broadly neutralizing antibodies (2016) (93)
Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19 (2020) (93)
Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion (2012) (93)
Regulation of human CD44H and CD44E isoform binding to hyaluronan by phorbol myristate acetate and anti-CD44 monoclonal and polyclonal antibodies. (1993) (93)
Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies (2011) (92)
Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. (2009) (92)
HIV-Specific Functional Antibody Responses in Breast Milk Mirror Those in Plasma and Are Primarily Mediated by IgG Antibodies (2011) (91)
Lessons learned from HIV-1 vaccine trials: new priorities and directions (2012) (90)
Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1 (2013) (90)
Elevation of Intact and Proteolytic Fragments of Acute Phase Proteins Constitutes the Earliest Systemic Antiviral Response in HIV-1 Infection (2010) (89)
Targeted selection of HIV-specific antibody mutations by engineering B cell maturation (2019) (89)
Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain (2016) (89)
Thymocyte LFA-1 and thymic epithelial cell ICAM-1 molecules mediate binding of activated human thymocytes to thymic epithelial cells. (1990) (88)
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. (2014) (88)
Differentiation of human T lymphocytes. I. Acquisition of a novel human cell surface protein (p80) during normal intrathymic T cell maturation. (1983) (87)
Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. (2017) (87)
Human thymic epithelial cells produce granulocyte and macrophage colony-stimulating factors. (1988) (87)
Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing (2012) (87)
Incorporation of High Levels of Chimeric Human Immunodeficiency Virus Envelope Glycoproteins into Virus-Like Particles (2007) (86)
HIV-1 gp120 Vaccine Induces Affinity Maturation in both New and Persistent Antibody Clonal Lineages (2012) (86)
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates (2006) (86)
Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies (2010) (86)
Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. (1990) (86)
Removal of fibroblasts from human epithelial cell cultures with use of a complement fixing monoclonal antibody reactive with human fibroblasts and monocytes/macrophages. (1989) (85)
Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. (1992) (85)
Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection (2011) (85)
Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses. (2008) (85)
Successful formation of a chimeric human thymus allograft following transplantation of cultured postnatal human thymus. (1997) (84)
The quest for an antibody‐based HIV vaccine (2017) (84)
Ontogeny of the human thymus during fetal development (1987) (84)
High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers (2013) (84)
Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population (2011) (84)
Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. (1991) (83)
A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies (2012) (82)
Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10 (2013) (81)
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys (2008) (81)
Initiation of immune tolerance–controlled HIV gp41 neutralizing B cell lineages (2016) (80)
HIV vaccines: where we are and where we are going (1996) (80)
Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity [ADCC] Responses (2013) (80)
Critical issues in mucosal immunity for HIV-1 vaccine development. (2008) (79)
Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. (2005) (78)
Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth (2018) (78)
Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy (2011) (78)
Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides. (1981) (78)
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. (2007) (78)
Developing an HIV vaccine (2017) (78)
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life (2013) (78)
Induction of HIV-1 Broad Neutralizing Antibodies in 2F5 Knock-in Mice: Selection against Membrane Proximal External Region–Associated Autoreactivity Limits T-Dependent Responses (2013) (77)
Human intrathymic T cell differentiation. (1990) (77)
Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques (2014) (77)
Monoclonal antibodies to CD2 and lymphocyte function-associated antigen 3 inhibit human thymic epithelial cell-dependent mature thymocyte activation. (1987) (76)
New approaches to HIV vaccine development. (2015) (76)
Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains (2014) (75)
N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. (1995) (75)
Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41 (2011) (74)
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers (2017) (73)
Thymoma: lymphoid and epithelial components mirror the phenotype of normal thymus. (1984) (73)
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (2019) (72)
Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein (2008) (72)
Utilization of Immunoglobulin G Fc Receptors by Human Immunodeficiency Virus Type 1: a Specific Role for Antibodies against the Membrane-Proximal External Region of gp41 (2009) (72)
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide (2017) (72)
In vitro growth and phenotypic characterization of mesodermal-derived and epithelial components of normal and abnormal human thymus. (1985) (72)
Differentiation of human T lymphocytes: II. Phenotypic difference in skin and blood malignant T-cells in cutaneous T-cell lymphoma. (1982) (72)
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. (2012) (72)
Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination (2008) (72)
HIV-1 Vaccines and Adaptive Trial Designs (2011) (71)
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. (2015) (70)
Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors (2013) (70)
Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection (2018) (70)
Stable Docking of Neutralizing Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Monoclonal Antibodies 2F5 and 4E10 Is Dependent on the Membrane Immersion Depth of Their Epitope Regions (2009) (69)
The human thymus (1998) (69)
In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of Immunity (2007) (69)
Structure and function of the CD7 molecule. (1999) (69)
Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env Immunogen (2006) (69)
Gamma (immune) interferon production by leukocytes from a patient with a TG cell proliferative disease. (1982) (68)
Structural diversity of the SARS-CoV-2 Omicron spike (2022) (68)
Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations (2017) (68)
Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees (2013) (67)
A human monoclonal antibody prevents malaria infection and defines a new site of vulnerability on Plasmodium falciparum circumsporozoite protein (2018) (67)
Human thymic epithelial cells function as accessory cells for autologous mature thymocyte activation. (1987) (67)
Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development (2018) (67)
The human thymus. A chimeric organ comprised of central and peripheral lymphoid components. (1998) (67)
Generation of CD8+ T-Cell Responses by a Recombinant Nonpathogenic Mycobacterium smegmatis Vaccine Vector Expressing Human Immunodeficiency Virus Type 1 Env (2006) (66)
Initial HIV-1 Antigen-Specific CD8+ T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication (2012) (66)
Analysis of expression of CD2, CD3, and T cell antigen receptor molecules during early human fetal thymic development. (1988) (66)
The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates (2021) (65)
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. (2015) (65)
The human thymic microenvironment. Phenotypic characterization of Hassall's bodies with the use of monoclonal antibodies. (1985) (65)
Use of immunosuppressive agents in the treatment of severe ocular and vascular manifestations of Cogan's syndrome. (1990) (65)
Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques (2019) (65)
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. (2013) (65)
Summary of T Cell Studies Performed during the Second International Workshop and Conference on Human Leukocyte Differentiation Antigens (1986) (65)
RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses (2018) (64)
Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution (2010) (64)
3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates (2020) (64)
Host Controls of HIV Neutralizing Antibodies (2014) (64)
A Signature in HIV-1 Envelope Leader Peptide Associated with Transition from Acute to Chronic Infection Impacts Envelope Processing and Infectivity (2011) (63)
Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. (2006) (63)
TNFalpha and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44. (1999) (62)
Host controls of HIV broadly neutralizing antibody development (2017) (62)
Dynamic Antibody Specificities and Virion Concentrations in Circulating Immune Complexes in Acute to Chronic HIV-1 Infection (2011) (62)
Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual (2011) (62)
Improving Defences at the Portal of HIV Entry: Mucosal and Innate Immunity (2008) (61)
Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity (2004) (61)
The human thymic microenvironment: cortical thymic epithelium is an antigenically distinct region of the thymic microenvironment. (1984) (61)
A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. (2004) (60)
Human erythrocyte antigens: II. The In(Lu) gene regulates expression of an antigen on an 80-kilodalton protein of human erythrocytes. (1984) (60)
CD44 antibody against In(Lu)-related p80, lymphocyte-homing receptor molecule inhibits the binding of human erythrocytes to T cells. (1989) (60)
Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. (2017) (59)
Ia+ T cells in new onset Graves' disease. (1984) (59)
Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design (2016) (59)
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. (2009) (59)
Human thymic epithelial cells directly induce activation of autologous immature thymocytes. (1988) (59)
Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting (2017) (58)
The human thymus (1998) (58)
Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity (2010) (58)
A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice (2021) (58)
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. (2014) (57)
Association of Wegener's granulomatosis with HLA-B8. (1979) (57)
Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. (2013) (57)
Differential Reactivity of Germ Line Allelic Variants of a Broadly Neutralizing HIV-1 Antibody to a gp41 Fusion Intermediate Conformation (2011) (57)
Primary Infection by a Human Immunodeficiency Virus with Atypical Coreceptor Tropism (2011) (57)
CCL3L1 and HIV/AIDS susceptibility (2009) (57)
Vaccine-Elicited V3 Loop-Specific Antibodies in Rhesus Monkeys and Control of a Simian-Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate Envelope (2001) (56)
Ligand binding to the LFA-3 cell adhesion molecule induces IL-1 production by human thymic epithelial cells. (1990) (56)
Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome (2012) (56)
Immune Distribution and Localization of Phosphoantigen-Specific Vγ2Vδ2 T Cells in Lymphoid and Nonlymphoid Tissues in Mycobacterium tuberculosis Infection (2007) (56)
Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys. (1993) (55)
Activation of human B lymphocytes. X. Heterogeneity of concanavalin A-generated suppressor cells of the pokeweed mitogen-induced plaque-forming cell response of human peripheral blood lymphocytes. (1978) (55)
Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. (2015) (55)
Human thymic epithelium and T cell development: current issues and future directions. (1990) (55)
Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines (2010) (55)
Human thymocytes bind to autologous and allogeneic thymic epithelial cells in vitro. (1986) (55)
Engraftment of human synovium into severe combined immune deficient mice. Migration of human peripheral blood T cells to engrafted human synovium and to mouse lymph nodes. (1993) (54)
High-Mannose Glycan-Dependent Epitopes Are Frequently Targeted in Broad Neutralizing Antibody Responses during Human Immunodeficiency Virus Type 1 Infection (2011) (54)
Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. (2008) (53)
Cell adhesion molecules involved in intrathymic T cell development. (1993) (53)
Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. (2014) (53)
Human Erythrocyte Antigens (1987) (52)
High throughput functional analysis of HIV-1 env genes without cloning. (2007) (52)
Contributions of Mamu-A*01 Status and TRIM5 Allele Expression, But Not CCL3L Copy Number Variation, to the Control of SIVmac251 Replication in Indian-Origin Rhesus Monkeys (2010) (52)
Candidate counterparts of Sézary cells and adult T-cell lymphoma-leukaemia cells in normal peripheral blood: an ultrastructural study with the immunogold method and monoclonal antibodies. (1983) (51)
B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. (2011) (51)
Synovial microenvironment-t cell interactions (1988) (51)
Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. (2018) (51)
Purified lymphocyte function-associated antigen-3 (LFA-3) activates human thymocytes via the CD2 pathway. (1988) (51)
Mechanisms of corticosteroid action on lymphocyte subpopulations. V. Effects of in vivo hydrocortisone on the circulatory kinetics and function of naturally occuring and mitogen-induced suppressor cells in man. (1979) (50)
Phenotypic characterization of human cytolytic T lymphocytes in mixed lymphocyte culture (1981) (50)
Immune reconstitution in patients with HIV infection. (2002) (50)
Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier (2018) (49)
Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. (2016) (49)
Thymic microenvironment induces HIV expression. Physiologic secretion of IL-6 by thymic epithelial cells up-regulates virus expression in chronically infected cells. (1991) (49)
Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple De Novo Genome Assemblies (2017) (49)
Longitudinal Analysis Reveals Early Development of Three MPER‐Directed Neutralizing Antibody Lineages from an HIV‐1‐Infected Individual (2019) (49)
Role of adhesion molecules in the pathogenesis of rheumatoid arthritis. (1995) (49)
Description of monoclonal antibody defining an HLA allotypic determinant that includes specificities within the B5 cross-reacting group. (1982) (49)
Characterization of human thymic epithelial cell surface antigens: Phenotypic similarity of thymic epithelial cells to epidermal keratinocytes (1995) (48)
Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection (2016) (48)
Loss of DNAM‐1 contributes to CD8+ T‐cell exhaustion in chronic HIV‐1 infection (2010) (48)
A novel activation pathway for mature thymocytes. Costimulation of CD2 (T,p50) and CD28 (T,p44) induces autocrine interleukin 2/interleukin 2 receptor-mediated cell proliferation (1988) (48)
Structure of an HIV-1–neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer (2014) (48)
CD7 and CD28 Are Required for Murine CD4+CD25+ Regulatory T Cell Homeostasis and Prevention of Thyroiditis1 (2004) (48)
CD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies (2014) (47)
Demonstration of abnormalities in expression of thymic epithelial surface antigens in severe cellular immunodeficiency diseases. (1983) (47)
Recombinant Mycobacterium bovis BCG Prime-Recombinant Adenovirus Boost Vaccination in Rhesus Monkeys Elicits Robust Polyfunctional Simian Immunodeficiency Virus-Specific T-Cell Responses (2009) (47)
Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region (2010) (46)
BCR and Endosomal TLR Signals Synergize to Increase AID Expression and Establish Central B Cell Tolerance. (2017) (46)
HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. (2012) (46)
Human postnatal CD4- CD8- CD3- thymic T cell precursors differentiate in vitro into T cell receptor delta-bearing cells. (1989) (46)
Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth (2020) (46)
SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. (2021) (46)
Monoclonal antibody 4F2 reactive with basal layer keratinocytes: studies in the normal and a hyperproliferative state. (1984) (46)
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions (2021) (46)
Characterization of a CD6 ligand(s) expressed on human- and murine-derived cell lines and murine lymphoid tissues. (1994) (45)
Isolation and characterization of the genomic human CD7 gene: structural similarity with the murine Thy-1 gene. (1991) (45)
Immunologic characterization of CD7-deficient mice. (1998) (45)
Safety and immunogenicity of an HLA‐based HIV envelope polyvalent synthetic peptide immunogen (1998) (45)
Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses (2017) (45)
Diabetes insipidus associated with Wegener's granulomatosis successfully treated with cyclophosphamide. (1978) (45)
Chromosome mapping of human cell surface molecules: Monoclonal anti-human lymphocyte antibodies 4F2, A3D8, and A1G3 define antigens controlled by different regions of chromosome 11 (1983) (45)
A tyrosine kinase physically associates with the beta-subunit of the human IL-2 receptor. (1991) (45)
Gut microbes out of control in HIV infection (2006) (44)
Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins (2004) (44)
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates (2013) (44)
HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection1 (2009) (43)
Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody That Recognizes a Novel Conformational Epitope on gp41 and Lacks Reactivity against Self-Antigens (2008) (43)
Coping with Viral Diversity in HIV Vaccine Design: A Response to Nickle et al (2008) (43)
Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies (2019) (43)
The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. (2009) (43)
A New Vaccine to Battle Covid-19 (2020) (43)
Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV (1984) (42)
Neutralizing IgG at the Portal of Infection Mediates Protection against Vaginal Simian/Human Immunodeficiency Virus Challenge (2013) (42)
Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection (2016) (42)
Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. (1993) (42)
Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. (2000) (42)
Pathogenic mechanisms of vessel damage in vasculitis syndromes. (1995) (42)
A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. (2013) (42)
Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. (2019) (42)
Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants (2013) (42)
Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. (2001) (41)
Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. (2011) (41)
Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk (2013) (41)
Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies (2021) (41)
Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8 (2016) (41)
Nonneutralizing HIV-1 gp41 Envelope Cluster II Human Monoclonal Antibodies Show Polyreactivity for Binding to Phospholipids and Protein Autoantigens (2010) (41)
Expression of CD44 molecules and CD44 ligands during human thymic fetal development: expression of CD44 isoforms is developmentally regulated. (1995) (41)
Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. (2006) (40)
Relatedness by nucleic acid hybridization of new isolates of human T-cell leukemia-lymphoma virus (HTLV) and demonstration of provirus in uncultured leukemic blood cells. (1983) (40)
Early corneal findings in Cogan's syndrome. (1984) (40)
Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation (2020) (40)
Cytokines and adhesion molecules in the pathogenesis of vasculitis (2000) (40)
Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals (2011) (38)
Structural diversity of the SARS-CoV-2 Omicron spike (2022) (38)
Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost (2015) (37)
Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. (2010) (37)
Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission (2015) (37)
Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. (2010) (37)
NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus. (1994) (37)
Cold sensitivity of the SARS-CoV-2 spike ectodomain (2020) (37)
Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth (2020) (37)
Leukemia inhibitory factor is a mediator of Escherichia coli lipopolysaccharide‐induced acute thymic atrophy (2002) (37)
Antigen‐specific B cell detection reagents: Use and quality control (2008) (37)
Strategies for eliciting HIV-1 inhibitory antibodies (2010) (37)
An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. (2004) (37)
Arthritis syndromes associated with human T cell lymphotropic virus type I infection. (1997) (37)
HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities (2014) (36)
Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies (2017) (36)
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees (2018) (36)
IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria (2014) (36)
Monoclonal antibodies reactive with human T cell lymphotropic virusI (HTLVI) p19 internal core protein: cross-reactivity with normal tissues and differential reactivity with HTLV types I and II. (1985) (36)
Phenotypic characterization and ontogeny of components of the human thymic microenvironment. (1984) (36)
Rapid Memory CD8+ T-Lymphocyte Induction through Priming with Recombinant Mycobacterium smegmatis (2006) (36)
Contribution of proteasome-catalyzed peptide cis-splicing to viral targeting by CD8+ T cells in HIV-1 infection (2019) (36)
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates (2021) (35)
HIV-1 intrapatient sequence diversity in the immunogenic V3 region. (1991) (35)
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial (2017) (35)
A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge (2018) (35)
Cold sensitivity of the SARS-CoV-2 spike ectodomain (2020) (35)
Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity (2016) (35)
Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity (2014) (35)
A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice (2021) (34)
Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies (2016) (34)
HIV mRNA Vaccines—Progress and Future Paths (2021) (34)
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (2019) (33)
Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements (2019) (33)
Distinct Kinetics of Gag-Specific CD4+ and CD8+ T Cell Responses during Acute HIV-1 Infection (2012) (33)
Activation of human B lymphocytes. V. Kinetics and mechanisms of suppression of plaque-forming cell responses by concanavalin A-generated suppressor cells. (1978) (33)
Single cell analysis of quiescent HIV infection reveals host transcriptional profiles that regulate proviral latency (2018) (33)
Effect of thymectomy on peripheral lymphocyte subsets in myasthenia gravis: selective effect on T-cells in patients with thymic atrophy. (1983) (33)
The role of adhesion molecules in epithelial-T-cell interactions in thymus and skin. (1990) (33)
Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques (2016) (33)
Immunodominant sites of human T cell lymphotropic virus type 1 envelope protein for murine helper T cells. (1989) (32)
Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike (2022) (32)
Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates (2021) (32)
The c-kit proto-oncogene receptor is expressed on a subset of human CD3-CD4-CD8- (triple-negative) thymocytes. (1994) (32)
Immune distribution and localization of phosphoantigen-specific Vgamma2Vdelta2 T cells in lymphoid and nonlymphoid tissues in Mycobacterium tuberculosis infection. (2008) (32)
A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. (2016) (32)
Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage (2015) (31)
Alteration of T-lymphocyte subpopulations in sarcoidosis. (1978) (31)
HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis (2018) (31)
Characterization of thymus-derived lymphocyte subsets in acute Epstein-Barr virus-induced infectious mononucleosis. (1979) (31)
Induction of Antibodies in Guinea Pigs and Rhesus Monkeys against the Human Immunodeficiency Virus Type 1 Envelope: Neutralization of Nonpathogenic and Pathogenic Primary Isolate Simian/Human Immunodeficiency Virus Strains (2000) (31)
Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum (2012) (31)
Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection (2016) (31)
Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. (2009) (31)
Constitutive expression of a groEL-related protein on the surface of human gamma/delta cells (1990) (31)
Functional association of CD7 with phosphatidylinositol 3-kinase: interaction via a YEDM motif. (1996) (31)
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. (2014) (30)
Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds (2016) (30)
HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development (2014) (30)
Systemic administration of an HIV 1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization (2016) (30)
HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies (2018) (29)
Improving Mycobacterium bovis Bacillus Calmette-Guèrin as a Vaccine Delivery Vector for Viral Antigens by Incorporation of Glycolipid Activators of NKT Cells (2014) (29)
Phenotypic and functional characterization of human malignant T cells. (1985) (29)
Human erythrocyte antigens. III. Characterization of a panel of murine monoclonal antibodies that react with human erythrocyte and erythroid precursor membranes. (1987) (29)
Interaction of pokeweed mitogen with monocytes in the activation of human lymphocytes. (1983) (29)
Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells (2021) (29)
The role of the thymic microenvironment in promotion of early stages of human T cell maturation. (1986) (29)
Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting (2019) (29)
Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa (2016) (28)
Resistance of CD7-deficient Mice to Lipopolysaccharide-induced Shock Syndromes (1999) (28)
Self-tolerance curtails the B cell repertoire to microbial epitopes. (2019) (28)
Leukemia-associated arthritis: identification of leukemic cells in synovial fluid using monoclonal and polyclonal antibodies. (1984) (28)
Generation of Mucosal Anti-Human Immunodeficiency Virus Type 1 T-Cell Responses by Recombinant Mycobacterium smegmatis▿ (2006) (28)
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial (2018) (28)
Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals (2011) (28)
Is developing an HIV-1 vaccine possible? (2010) (28)
Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF. (1996) (28)
Expression of early activation antigen (CD69) during human thymic development (1990) (28)
Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates (2019) (27)
Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism (1995) (27)
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research (2015) (27)
Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. (2002) (27)
Functional, Non-Clonal IgMa-Restricted B Cell Receptor Interactions with the HIV-1 Envelope gp41 Membrane Proximal External Region (2009) (27)
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates (2021) (27)
Epithelial-thymocyte interactions in human thymus. (1987) (27)
Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Elicits Human Immunodeficiency Virus Type 1 Envelope-Specific T Lymphocytes at Mucosal Sites (2007) (27)
Development of suppressor T lymphocytes for Epstein-Barr virus-induced B-lymphocyte outgrowth during acute infectious mononucleosis: assessment by two quantitative systems. (1981) (27)
Aggregate complexes of HIV-1 induced by multimeric antibodies (2014) (27)
Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. (2020) (27)
Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies (2013) (27)
Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations (2019) (26)
HIV-1 hides an Achilles' heel in virion lipids. (2008) (26)
Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection. (2007) (26)
Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies (2019) (26)
D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1/S2 junction (2020) (26)
Cross-reactivity of HIV vaccine responses and the microbiome (2018) (26)
Activated T Lymphocytes Regulate Hyaluronan Binding to Monocyte CD44 Via Production of IL-2 and IFN-γ1 (2001) (26)
Centralized HIV-1 envelope immunogens and neutralizing antibodies. (2007) (25)
A comparison of murine T-cell-depleted adult bone marrow and full-term fetal blood cells in hematopoietic engraftment and immune reconstitution. (2002) (25)
A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies (2020) (25)
Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants (2020) (25)
The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template (2019) (25)
Activation of human B lymphocytes. XIII. Characterization of multiple populations of naturally occurring immunoregulatory cells of polyclonally induced in vitro human B cell function. (1979) (25)
Analysis of clones derived from human CD7+CD4-CD8-CD3- thymocytes. (1991) (25)
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice (2021) (24)
Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. (2015) (24)
Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1 (2010) (24)
IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells (2018) (24)
Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk (2016) (24)
Induction of T cell CD7 gene transcription by nonmitogenic ionomycin-induced transmembrane calcium flux. (1991) (24)
V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity (2018) (24)
Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. (2011) (24)
The thymic microenvironment. Characterization of in vitro differentiation of the IT26R21 rat thymic epithelial cell line. (1987) (24)
Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. (1999) (24)
Designing synthetic vaccines for HIV (2015) (24)
HIV Molecular Immunology 2001 (2001) (24)
Computer Assisted Tomography of Orbital Lesions in Wegener's Granulomatosis (1978) (23)
Synovial microenvironment-T cell interactions. Human T cells bind to fibroblast-like synovial cells in vitro. (1988) (23)
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice (2021) (23)
Human medullary thymocyte p80 antigen and In(Lu)-related p80 antigen reside on the same protein. (1986) (23)
HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope (2018) (23)
Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants (2015) (23)
Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C (2013) (23)
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine (2017) (22)
Intranasal Vaccination with the Recombinant Listeria monocytogenes ΔactA prfA* Mutant Elicits Robust Systemic and Pulmonary Cellular Responses and Secretory Mucosal IgA (2011) (22)
Immune checkpoint modulation enhances HIV-1 antibody induction (2020) (22)
Restricted isotype, distinct variable gene usage, and high rate of gp120-specificity of HIV-1 Envelope-specific B cells in colostrum compared to those in blood of HIV-1-infected, lactating African women (2014) (22)
The Exon A (C77G) Mutation Is a Common Cause of Abnormal CD45 Splicing in Humans1 (2001) (22)
Stromal cell independent B cell development in vitro: generation and recovery of autoreactive clones. (2010) (22)
HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? (2010) (22)
Differentiation of human T cells. (1988) (22)
Increase in TCRγδ T lymphocytes in synovia from rheumatoid arthritis patients with active synovitis (1992) (21)
Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge (2017) (21)
Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection (2017) (21)
Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials (2021) (21)
Normalization of the Peripheral Blood T Cell Receptor Vβ Repertoire After Cultured Postnatal Human Thymic Transplantation in DiGeorge Syndrome (1997) (21)
Expression of antigens by cultured epithelial cells: comparison of epidermis and thymic epithelium. (1985) (20)
C-terminal region of human T cell lymphotropic virus type I (HTLVI) p19 core protein is immunogenic in humans and contains an HTLVI-specific epitope. (1986) (20)
Inhibition of HIV type 1 infection of mononuclear phagocytes by anti-CD44 antibodies. (1995) (20)
Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells (2020) (20)
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. (2015) (20)
The HLA antigens in Cogan's syndrome. (1978) (19)
Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors (2021) (19)
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice (2021) (19)
Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein (1993) (19)
HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen. (1995) (19)
Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site (2018) (19)
of Human and Rodent (1983) (19)
Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide (2014) (19)
Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1 (2017) (19)
Naïve T Cells Are Maintained in the Periphery During the First3 Months of Acute HIV-1 Infection: Implications for Analysis of Thymus Function (2005) (19)
Quantitative and Qualitative Differences in the T Cell Response to HIV in Uninfected Ugandans Exposed or Unexposed to HIV-Infected Partners (2013) (18)
Expression of the CD7 Ligand K-12 in Human Thymic Epithelial Cells: Regulation by IFN-γ (2005) (18)
Comparison of thymocyte development and cytokine production in CD7-deficient, CD28-deficient and CD7/CD28 double-deficient mice. (2001) (18)
Dramatic remissions in severe systemic necrotizing vasculitis (SNV) with cyclophosphamide (CY) therapy (1979) (18)
Distribution of CD44 variant isoforms in human skin: differential expression in components of benign and malignant epithelia (1995) (18)
Localization of collagenase mRNA in rheumatoid arthritis synovium byin situ hybridization histochemistry (2004) (18)
Leukocyte Typing II (1986) (17)
Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization (2020) (17)
Broadly Neutralizing Antibodies and the Development of Vaccines. (2015) (17)
Diagnostic and therapeutic approach to the patient with vasculitis. (1986) (17)
The human thymic microenvironment during organ culture. (1997) (17)
Improved Killing of HIV-infected Cells Using Three Neutralizing and Non-neutralizing Antibodies. (2020) (17)
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques (2017) (17)
Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies (2019) (17)
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant (2018) (17)
Modulation of Nonneutralizing HIV-1 gp41 Responses by an MHC-Restricted TH Epitope Overlapping Those of Membrane Proximal External Region Broadly Neutralizing Antibodies (2014) (17)
Mollaret meningitis. A report of three cases. (1976) (17)
Expression of CD44 variants in human inflammatory synovitis (1995) (17)
The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells (2015) (17)
Phenotypic characterization of human bone marrow granulocyte-macrophage forming progenitor cells. (1981) (16)
Immune responses of human lymphocytes in vitro. (1980) (16)
Analysis of Fcγ receptors on human peripheral blood leukocytes by flow microfluorometry. I. Receptor distributions on monocytes, Tγ cells and cells labeled with the 3A1 anti‐T cell monoclonal antibody (1982) (16)
T cell CD7 mRNA expression is regulated by both transcriptional and post-transcriptional mechanisms. (1993) (16)
An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion (2022) (16)
Leukocyte homing to synovium. (2001) (16)
Erratum: Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection (The Journal of Clinical Investigation (1999) 103 (453- 460)) (1999) (16)
CD34+CD38-lin- cord blood cells develop into dendritic cells in human thymic stromal monolayers and thymic nodules. (1998) (16)
Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee☆ (2015) (16)
Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation (2018) (15)
Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users (2014) (15)
Correction: Thy1+ Nk Cells from Vaccinia Virus-Primed Mice Confer Protection against Vaccinia Virus Challenge in the Absence of Adaptive Lymphocytes (2011) (15)
Gender Differences in Human Immunodeficiency Virus Type 1-Specific CD8 Responses in the Reproductive Tract and Colon following Nasal Peptide Priming and Modified Vaccinia Virus Ankara Boosting (2004) (15)
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women (2017) (15)
Increase in TCR gamma delta T lymphocytes in synovia from rheumatoid arthritis patients with active synovitis. (1992) (15)
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency (2019) (15)
Rheumatoid arthritis and sterile corneal ulceration (1984) (15)
Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins (2010) (15)
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. (2020) (15)
Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells. (2012) (15)
Heterogeneity of acute lymphocytic leukemia cell surface markers as detected by monoclonal antibodies. (1983) (15)
The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells. (2014) (15)
Progress in HIV-1 vaccine development (2013) (15)
Thymic function, aging, and AIDS. (1999) (15)
Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine (2022) (15)
Human T-cell lymphotropic virus I and adult T-cell leukemia: report of a cluster in North Carolina. (1988) (14)
HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. (2017) (14)
Mechanism of Epstein-Barr virus-induced human B-lymphocyte activation. (1980) (14)
A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro (2010) (14)
The role of leukocyte adhesion molecules in cellular interactions: Implications for the pathogenesis of inflammatory synovitis (2004) (14)
Vaccine Innovations - Past and Future. (2021) (14)
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies (2022) (14)
Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors (2015) (13)
Strategies for induction of HIV‐1 envelope‐reactive broadly neutralizing antibodies (2021) (13)
Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Vectors Prime for Strong Cellular Responses to Simian Immunodeficiency Virus Gag in Rhesus Macaques (2014) (13)
Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates (2020) (13)
Characterization of human CD7 transgenic mice. (1995) (13)
Gene Deletions in Mycobacterium bovis BCG Stimulate Increased CD8+ T Cell Responses (2014) (13)
Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection (2018) (13)
Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation (2014) (13)
Towards a genomic-based diagnosis (2001) (13)
Analysis of corneal and conjunctival microenvironments using monoclonal antibodies. (1993) (13)
Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection (2015) (12)
Developmental regulation of lymphocyte-specific protein 1 (LSP1) expression in thymus during human T-cell maturation. (1998) (12)
Demonstration of phenotypic abnormalities of thymic epithelium in thymoma including two cases with abundant Langerhans cells. (1988) (12)
Monoclonal Antibodies: Probes for the Study of Autoimmunity and Immunodeficiency (1983) (12)
HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site (2017) (12)
HIV infection and the dynamic interplay between the thymus and the peripheral T cell pool. (1999) (12)
Characterization of the surface topography and putative tertiary structure of the human CD7 molecule. (1989) (12)
Innate immune responses in acute HIV-1 infection: protective or pathogenic? (2013) (12)
Comparison of the CD7 (3A1) Group of T Cell Workshop Antibodies (1986) (12)
Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. (1998) (12)
Gamma (immune) interferon production by leukocytes from a patient with a TG cell proliferative disease (1982) (11)
Gamma (immune) interferon production by leukocytes from a patient with a TG cell proliferative disease (1982) (11)
Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector (2019) (11)
New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure (2021) (11)
Computational analysis of antibody dynamics identifies recent HIV-1 infection. (2017) (11)
Eliminating antibody polyreactivity through addition of N‐linked glycosylation (2015) (11)
Transcriptional network predicts viral set point during acute HIV-1 infection (2012) (11)
HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence (2015) (11)
Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques (2020) (11)
Redemption of autoreactive B cells (2014) (11)
Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. (2016) (11)
Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies (2013) (11)
Enhanced Antibody Responses to an HIV-1 Membrane-Proximal External Region Antigen in Mice Reconstituted with Cultured Lymphocytes (2014) (10)
Leukocyte Typing II (1986) (10)
Methods development for Analysis of Partially Deglycosylated Proteins and Application to an HIV Envelope Protein Vaccine Candidate. (2011) (10)
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination (2021) (10)
What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. (2018) (10)
AD2, a human molecule involved in the interaction of T cells with epidermal keratinocytes and thymic epithelial cells. (1995) (10)
HIV Molecular Immunology 2014 (2015) (10)
Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. (2016) (10)
Evidence for susceptibility of intrathymic T cell precursors to human immunodeficiency virus infection: a mechanism for T4 (CD4) lymphocyte depletion. (1990) (10)
Monoclonal antibodies to a human islet cell surface glycoprotein: 4F2 and LC7-2. (1987) (10)
Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement. (1987) (10)
HIV Molecular Immunology 2015 (2016) (9)
Linkage of the CCR5Δ32 Mutation with a Functional Polymorphism of CD45RA1 (2000) (9)
Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. (2016) (9)
P04-48. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after gp120 protein vaccination or chronic HIV-1 infection (2009) (9)
Hemolytic Transfusion Reactions Caused by Failure of Commercial Antiglobulin Reagents To Detect Complement (2003) (9)
A visual assay to monitor purification of cell surface antigens reacting with monoclonal antibodies. (1980) (9)
Nuclear Magnetic Resonance Analysis of Solution Conformations in C4-V3 Hybrid Peptides Derived from Human Immunodeficiency Virus (HIV) Type 1 gp120: Relation to Specificity of Peptide-Induced Anti-HIV Neutralizing Antibodies (1999) (9)
Envelope Epitopes Glycoprotein 41 Membrane Proximal Monoclonal Antibodies 2 F 5 and 4 E 10 to Neutralizing Anti-HIV-1 Envelope Human Lipid Reactivity in Binding of Broadly The Role of Antibody Polyspecificity and Haynes (2007) (9)
HIV-Selectest Enzyme Immunoassay and Rapid Test: Ability To Detect Seroconversion following HIV-1 Infection (2009) (9)
All known cross-reactive HIV-1 neutralizing antibodies are highly divergent from germline and their elicitation may require prolonged periods of time (2008) (9)
Activation of human B lymphocytes. VI. Immunoregulation of antibody production by mitogen-induced and naturally occurring cells in normal individuals. (1978) (8)
Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination. (2021) (8)
mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice (2022) (8)
Lessons from babies: inducing HIV-1 broadly neutralizing antibodies (2014) (8)
Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5 (2019) (8)
Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin. (1990) (8)
Linkage of the CCR5 Delta 32 mutation with a functional polymorphism of CD45RA. (2000) (8)
A monoclonal antibody reactive with a second epitope of the 67,000-dalton human T cell antigen. (1983) (8)
Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy. (1993) (8)
Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions (2020) (7)
Analysis of HLA Frequencies in Population Cohorts for Design of HLA-Based HIV Vaccines (1995) (7)
Update on the issues of HIV vaccine development. (1996) (7)
Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections. (1995) (7)
Lack of generation of killer cells in the mixed lymphocyte reaction between mitogen-stimulated and unstimulated autologous lymphocytes. (1978) (7)
Monoclonal antibodies against human t cell leukemia-lymphoma virus (htlv) p25 internal core protein. (1984) (7)
Thymic epithelial-cell-derived cytokines and their roles in thymic precursor cell differentiation (1990) (7)
Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity (2020) (7)
SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys (2021) (7)
Antibody against T lymphoblastic leukemia-associated antigen (3-40) identifies vimentin and keratin intermediate filaments in normal cells. (1985) (7)
New frontiers of immunotherapy for HIV (1996) (7)
Flow Cytometry Sorting of Recombinant Mycobacterial Species Yields Bacterial Clones with Enhanced Insert Expression (2010) (7)
HIV in Lymph Node and Thymus (1996) (6)
Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates (2018) (6)
Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial (2020) (6)
SARS-CoV-2 and HIV-1 — a tale of two vaccines (2021) (6)
Activation of human B lymphocytes. XIV. Characterization of the precursor of the pokeweed mitogen-induced anti-sheep red blood cell plaque-forming cell. (1979) (6)
Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin (2020) (6)
Characterization of a monoclonal antibody, RTE-21, that binds to keratohyalin granule-associated proteins in epithelial cells of human skin and thymus. (1986) (6)
Activation of interleukin 4- and interleukin 6-secreting cells by HIV-specific synthetic peptides. (1995) (6)
Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4. (1997) (6)
Production of a Thymosin α1-like Material by T-Cell Lymphomas (1984) (5)
HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism (2016) (5)
Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity (2013) (5)
Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice (2017) (5)
CHAPTER 2 – POKEWEED MITOGEN-INDUCED PFC RESPONSES OF HUMAN PERIPHERAL BLOOD LYMPHOCYTES: REGULATION OF B-CELL TRIGGERING (1979) (5)
Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs (2020) (5)
HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers (2019) (5)
Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology. (2019) (5)
Human T-cell leukemia/lymphoma virus: studies of host-virus interaction. (1985) (5)
Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations (2021) (5)
The mouse CD7 gene: identification of a new element common to the human CD7 and mouse Thy-1 promoters (1996) (5)
Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans (2019) (5)
HLA and Cogan's syndrome. (1978) (5)
A New Model for Catalyzing Translational Science: The Early Stage Investigator Mentored Research Scholar Program in HIV Vaccines (2015) (4)
Influenza vaccines: mTOR inhibition surprisingly leads to protection (2013) (4)
Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models (2020) (4)
In vivo models of human lymphopoiesis and autoimmunity in severe combined immune deficient mice (1992) (4)
Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism (2022) (4)
Polyspecific reactivity of a murine monoclonal antibody that binds to nuclear matrix-associated, chromatin-bound autoantigens. (1987) (4)
Identification and Characterization of a 100-kD Ligand for CD 6 on Human Thymic Epithelial Cells (2003) (4)
Use of Monoclonal Antibodies to Identify Antigens of Human Endocrine Thymic Epithelium (1984) (4)
New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure (2021) (4)
Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles (2021) (4)
Enhanced Priming of Adaptive Immunity by Mycobacterium smegmatis Mutants with High-Level Protein Secretion (2012) (4)
Correction: Copy Number Variation of KIR Genes Influences HIV-1 Control (2011) (4)
lymphohematopoietic cells CD7+, CD4-, CD8- acute leukemia: a syndrome of malignant pluripotent (2011) (4)
Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor 6-chain diversity region and results in a previously unreported fusion transcript ( differentiation / karyotype / SCL gene / hemopoietic development ) (4)
T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial (2012) (4)
142 HIV Frequently Elicits Mucosal and Plasma Env-Specific IgA With a Rapid Initial Decline In Acute Infection (2009) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
T Helper-suppressor Cell Imbalance in Pyoderma Gangrenosum, with Relapsing Polychondritis and Corneal Keratolysis (1983) (4)
P09-21 LB. Deep sequencing of HIV-1 from acute infection: low initial diversity, and rapid but variable CTL escape (2009) (4)
Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART® Molecules (2021) (3)
Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques (2020) (3)
Corrigendum to “T Cell receptor excision circle assessment of thymopoieses in aging mice” [MIMM (2001) 38 (11) 841–848] (2002) (3)
P01-01. The blood transcriptional response to early acute HIV infection is transient and responsive to antiretroviral therapy (2009) (3)
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family (2012) (3)
Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs (2020) (3)
PURIFIED LFA-3 ANTIGEN ACTIVATES HUMAN THYMOCYTES VIA THE CD2 PATHWAY (1988) (3)
Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection (2022) (3)
Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteins. (2010) (3)
Analysis of Fc gamma receptors on human peripheral blood leukocytes by flow microfluorometry. I. Receptor distributions on monocytes, T gamma cells and cells labeled with the 3Al anti-T cell monoclonal antibody. (1982) (3)
Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials (2020) (3)
Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements (2020) (3)
Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. (2014) (3)
Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center (2021) (3)
HIV-1 infection – induced apoptotic microparticles inhibit human DCs via CD 44 (2012) (3)
HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth (2021) (3)
Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite (2018) (3)
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies (2021) (3)
The Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies (2015) (3)
Severe combined immunodeficiency (SCID) with natural killer (NK) cell predominance. (1983) (3)
A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite (2018) (3)
Conformational Epitope Mediates Potent ADCC Activity and Defines a Common 2 (2011) (3)
Subordinate effect of −21M HLA-B dimorphism on NK cell repertoire diversity and function in HIV-1 infected individuals of African origin (2019) (3)
DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies (2012) (2)
Chapter 3 – Use of Monoclonal Antibodies to Identify Cell-Surface Antigens of Human Neuroendocrine Thymic Epithelium1 (1983) (2)
Stage-specific adhesion molecules in human intrathymic T-cell development. (1994) (2)
Boosting with ALVAC-HIV and AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity (2019) (2)
Dynamic Antibody Speciﬁcities and Virion Concentrations in Circulating Immune Complexes in Acute to Chronic HIV-1 Infection (cid:1) † (2011) (2)
Monoclonal antibody defines human cell surface protein p80 on intrathymic T cells. (1984) (2)
Conditional Antibody Expression to Avoid Central B Cell Deletion in a Humanized HIV-1 Vaccine Mouse Models (2020) (2)
Rheumatoid arthritis and sterile corneal ulceration. Analysis of tissue immune effector cells and ocular epithelial antigens using monoclonal antibodies. (1984) (2)
15. Differential effects of in vivo hydrocortisone on human T cell subpopulations (1978) (2)
Single-cell analysis of immune cell transcriptome during HIV-1 infection and therapy (2022) (2)
Phenotypic and Functional Characterization of Natural Killer Cells by Monoclonal Antibodies (1982) (2)
HIV-1 Vpu restricts Fc-mediated effector functions in vivo (2022) (2)
The Spectrum of Vasculitis (2020) (2)
Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations (2019) (2)
Characterization of concanavalin a generated suppressor cells of the plaque forming cell response of human peripheral blood lymphocytes (1977) (2)
The mouseCD7 gene: Identification of a new element common to the humanCD7 and mouseThy-1 promoters (2007) (2)
antigen on an 80-kilodalton protein of human erythrocytes Human erythrocyte antigens: II. The In(Lu) gene regulates expression of an (2011) (2)
CYTOLYTIC T LYMPHOCYTES IN MIXED LYMPHOCYTE CULTURE (1981) (2)
Functional Improbable Antibody Mutations Critical for HIV Broadly Neutralizing Antibody Development (2018) (2)
Priming of anti-human immunodeficiency virus ( HIV ) CD 8 + cytotoxic T cells in vivo by carrier-free HIV synthetic peptides ( immunlzation / vwcdne / retrovirus ) (2)
Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor (2020) (2)
Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 (2012) (2)
OA021-04. HIV-1 gp41 envelope MPER mutation altered epitope conformation in lipid and increased sensitivity to 2F5 and 4E10 neutralizing antibodies (2009) (2)
HIV-1 Vaccine Development (2015) (2)
P04-44. Generation of antibody responses to HIV-1 membrane proximal external region (MPER) antigen (2009) (2)
S01-04 OA. Phenotypic analyses of CD8+ T cells that mediate virus inhibition from HIV-1 vaccinees and HIV-1+ virus controllers (2009) (2)
P04-45. Characterization of the plasma cell repertoire in acute HIV-1 infection (AHI) (2009) (2)
Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. (2017) (2)
Comparison of the relative cytotoxic effector cell capabilities and the proportions of cells bearing various surface markers in human tonsil and peripheral blood mononuclear cells. (1978) (2)
Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein (2012) (2)
P04-01. Simultaneous enumeration of HIV-1 gp41 Env-specific IgG and IgM antibody-secreting cells with a multiplex B-cell fluorospot assay (2009) (2)
Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1 (2019) (2)
Selective inhibition of natural killer activity by the monoclonal antibodies OKT10 and VEP10 at the single cell level. (1984) (2)
Chimpanzee SIV Envelope trimer: structure and deployment as an HIV vaccine template (2018) (2)
CHAPTER 19 – EFFECT OF HYDROCORTISONE ON THE KINETICS AND FUNCTION OF PERIPHERAL BLOOD IMMUNOREGULATORY CELLS IN MAN (1979) (2)
Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies (2021) (2)
Ontogeny of Human T Cell Antigens (1986) (2)
Gamma (immune) interferon produced by leukocytes from a patients with a T cell proliferation disease. (1981) (2)
Erratum for Tolbert et al., “Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial” (2021) (1)
Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation (2014) (1)
Preclinical development of a bispecific HIV x CD3 DART molecule that redirects T cells to kill HIV envelope (env)-expressing cells (2017) (1)
SIV vaccine protection of rhesus monkeys. (1991) (1)
HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer (2018) (1)
Identi fi cation of amino acid substitutions associated with neutralization phenotype in the human immunode fi ciency virus type-1 subtype C gp 120 (2016) (1)
Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 Infection (2022) (1)
COVID-19 Diagnosis and SARS-CoV-2 Strain Identification by a Rapid, Multiplexed, Point-of-Care Antibody Microarray (2023) (1)
MULTIPLE SUBPOPULATIONS OF LYMPHOID CELLS REGULATING HUMAN B CELL FUNCTION (1979) (1)
Acquisition of a Novel T Cell Surface Protein During Intrathymic T Cell Maturation Encoded for by the Short Arm of Chromosome 11 (1984) (1)
Author Correction: SARS-CoV-2 and HIV-1 – A Tale of Two Vaccines (2021) (1)
116 Autologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection (2012) (1)
Identification and Characterization of a 100-kD Ligand for CD6 on Human Thymic Epithelial Cells By Dhavalkumar D. Patel,* Siow-Fong Wee,~ Leona P. Whichard,* (1995) (1)
Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome (2012) (1)
Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial (2021) (1)
Can the thymus win the battle against drug-resistant HIV? (2001) (1)
Reviewers for the Journal, January-June 2016. (2016) (1)
Germline-targeting and Reverse Engineering to Elicit CH235.12 Lineage bNAbs (2018) (1)
Erratum: Lessons learned from HIV-1 vaccine trials: new priorities and directions (2013) (1)
Response: HIV Quasispecies and Resampling. (1996) (1)
HIV vaccine development at duke university medical center (2000) (1)
Abstracts of the 8th HIV Persistence during Therapy Workshop (2017) (1)
New surrogate markers for autoimmune disease activity. (1998) (1)
Kynureninase is the conserved self-antigen mimicked by the 2F5 Neutralizing Epitope of HIV-1 gp41 (105.35) (2012) (1)
Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques (2020) (1)
Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield (2022) (1)
Expression of membrane Hsp90 is a molecular signature of T cell activation (2022) (1)
Disease diagnostics using machine learning of immune receptors (2022) (1)
Response: HIV Viral Load Assay. (1996) (1)
Protein Vaccination or HIV-1 Infection Antibody Levels after Envelope gp 120 Responses That Correlate with Plasma HIV-1 Envelope Induces Memory (2009) (1)
A-102 Antibody binding to HIV-1 infected cells as mechanism for treatment of HIV infection (2018) (1)
B-Cell Development and Differentiation During HIV Infection: Tolerance Versus Immunity (2010) (1)
Virion Capture by HIV-1 gp 120-Specific IgG from RV 144 Vaccinees (2013) (1)
From the Institute of Medicine. (1994) (1)
The future of rheumatoid arthritis treatment. (1993) (1)
Aggregate complexes of HIV-1 induced by multimeric antibodies (2014) (1)
CHAPTER 23 – ABERRANT REGULATION OF B-CELL FUNCTION IN IMMUNOLOGICALLY MEDIATED DISEASES: SYSTEMIC LUPUS ERYTHEMATOSUS AND SARCOIDOSIS (1979) (1)
Murine CD7 shares antigenic cross-reactivity with HSP-60. (2008) (1)
Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV (2018) (1)
safety evaluations in 12 patients Thymus transplantation in complete DiGeorge syndrome: immunologic and (2013) (1)
The challenges of an HIV vaccine enterprise - Response (2004) (1)
Gene Therapy for HIV Infection (1994) (1)
Interferon-gamma Responses to HIV-1 Clade A and D Peptides in Ugandan Serodiscordant Couples - the CHAVI 002 Protocol (2008) (1)
V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site (2012) (1)
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family (2012) (1)
Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial (2012) (1)
Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes (2012) (1)
Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial (2012) (1)
Postnatally-transmitted HIV-1 variants are efficient at dendritic cell trans-infection and sensitive to autologous and heterologous neutralization (2012) (1)
Improved killing of HIV-infected cells by a combination of three antibodies: implications for clearing persistent infection (2019) (0)
Subtype C-Infected Individual HIV-1 Neutralizing-Antibody Response in an Represents the Initial Autologous Targets the Alpha-2 Helix of gp120 and Isolation of a Monoclonal Antibody That (2011) (0)
Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1 (2022) (0)
Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions (2023) (0)
Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1 (2022) (0)
Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment (2010) (0)
The role of immunological tolerance in humoral responses to the 2F5 epitope of HIV-1 (P6183) (2013) (0)
-Membrane Proximal External Region Antibodies in 2F5 Knock-in Mice: Selection Induction of HIV-1 Broad Neutralizing (2013) (0)
of the Malignant T Cell in Sezary Syndrome and Mycosis Fungoides (1981) (0)
Corrigendum to: Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes [Virology 475 (2015) 37–45] (2015) (0)
g Production of IL-2 and IFN-Hyaluronan Binding to Monocyte CD44 Via Activated T Lymphocytes Regulate (2000) (0)
Crystal structure of RV144-elicited antibody CH58 (2013) (0)
IMMUNOTHERAPY FOR HIV. AUTHOR'S REPLY (1997) (0)
Monoclonal Antibodies Probes for the Study of Malignant T Cells (1985) (0)
Post-Chemotherapeutic Hematopoietic Reconstitution: A Transgenic Mouse Model. (1996) (0)
Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens (2012) (0)
Humans Cause of Abnormal CD 45 Splicing in The Exon A ( C 77 G ) Mutation Is a Common (2001) (0)
STRUCTURE OF THE ANTI-HIV ANTIBODY DH501 THAT BINDS GP120 V3 GLYCAN AND THE BASE OF V3 WITH FREE MAN9 GLYCAN (2017) (0)
SuccessfulEngraftmentofHuman PostnatalThymus inSevereCombined Immune Deficient(SCID)Mice: Differential EngraftmentofThymic Components With Irradiation VersusAnti-asialo GM-1 ImmunosuppressiveRegimens (1991) (0)
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine (2022) (0)
Lipids, Limit Production of HIV-1 Broad Cross-Reactivities Associated with gp41 and Common Tolerance Mechanisms, but Distinct (2013) (0)
Structural Analysis of the Unmutated Ancestor of the HIV-1 Envelope V2 Region Antibody CH58 Isolated From an RV144 HIV-1 Vaccine Efficacy Trial Vaccinee and Associated with Decreased Transmission Risk (2015) (0)
HIV-1 Germline-Targeting Vaccine Regimen Selects for Rare Immunoglobulin Insertions and Deletions Typical of VRC01-Class Antibodies (2022) (0)
Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies (2019) (0)
Response : HIV Viral Load Assay (1996) (0)
Lipopolysaccharide-Induced Thymic Atrophy Leptin Deficiency and Leptin Selectively Augments Thymopoiesis in (2006) (0)
Identification of a conserved self-antigen bearing the 2F5 neutralizing epitope of the HIV-1 gp41 Membrane Proximal External Region (105.2) (2011) (0)
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates (2021) (0)
Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor (2023) (0)
A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies (2022) (0)
A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge (2018) (0)
Effects of Purine Nucleosides on Differentiation in Lymphohematopoietic Stem Cell Leukemia (1987) (0)
Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived peptide in a helical conformation (2010) (0)
Crystal Structure of DH511.2 Fab in Complex with HIV-1 gp41 MPER 670-683 Peptide (2017) (0)
C106 Distinguishing Features of Transmitted/Founder HIV-1 (2013) (0)
Cryo-EM structure of HIV-1 neutralizing antibody DH270 UCA3 in complex with CH848 10.17DT Env (2019) (0)
Associated Autoreactivity Limits − against Membrane Proximal External Region Antibodies in 2 F 5 Knockin Mice : Selection Induction of HIV-1 Broad Neutralizing (2013) (0)
114 Role of Vaccine-induced V2 Antibodies in Protection From HIV Infection of Recipients in the RV144 Clinical Vaccine Trial (2012) (0)
Correlates of Protective Viruses Damaging to HIV Infection (1996) (0)
Protection from death in endotoxin shock: does fish oil need a LIF? (2002) (0)
Crystal structure of RV144-elicited antibody CH58 in complex with V2 peptide (2013) (0)
Streamlined quasispecies and subtype analysis of HIV-1 sequences generated by high-throughput sequencing using the high-performance integrated virtual environment (HIVE) (2016) (0)
Immune checkpoint modulation enhances HIV-1 antibody induction (2020) (0)
Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center (2021) (0)
Incorporation of High Levels of Chimeric Human Immunodeﬁciency Virus Envelope Glycoproteins into Virus-Like Particles (cid:1) (2007) (0)
Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1 (2022) (0)
Crystal Structure of DH511.2 Fab in Complex with HIV-1 gp41 MPER 662-683 Peptide (2017) (0)
Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection (2018) (0)
Brief DeBnitive Report (2003) (0)
DH reading frame usage influences HIV-1 epitope recognition (MPF2P.804) (2014) (0)
Structural Constraints of V accine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting (2015) (0)
Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies (2019) (0)
Isolation of monoclonal antibodies targeting HLA-E/HIV-1 and SIV peptide complexes (2019) (0)
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults (2023) (0)
Engineered Immunogens to Expose Conserved Epitopes Targeted by Broad Coronavirus Antibodies (2023) (0)
E104 Identification of Three Distinct Epitope Regions in the V2 Portion of gp120 (2013) (0)
Examining HIV-1 envelope conformational transitions at high temporal resolution. (2023) (0)
Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors (2022) (0)
, In Vivo Infection Improves Protection against Lentiviral In Vitro Neutralizing HIV-1 Antibody Enhanced Potency of a Broadly (2014) (0)
Author Correction: Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies (2023) (0)
HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope (2018) (0)
Legionnaires ' Disease and Acinetobacter Bacteremia (2009) (0)
Vaccine induction of CD4-mimicking broadly neutralizing antibody precursors in macaques (2023) (0)
Structural and Functional Studies of Experimental HIV Synthetic Peptide Immunogens (1996) (0)
Mutation-Guided Vaccine Design: A Strategy for Developing Boosting Immunogens for HIV Broadly Neutralizing Antibody Induction (2022) (0)
Linkage of the CCR5D32 Mutation with a Functional Polymorphism of CD45RA (2000) (0)
Antibody 3–40 Binds to Keratin and Vimentin Intermediate Filaments (1986) (0)
784 Thymic output after non-ablative allogeneic hematopoietic stem cell transplantation in infants with severe combined immunodeficiency (SCID) (2000) (0)
Independently verified structure of gp41-M-MAT, a membrane associated MPER trimer from HIV-1 gp41 (2013) (0)
identifies vimentin and keratin intermediate filaments in normal cells Antibody against T lymphoblastic leukemia-associated antigen (3-40) (2011) (0)
Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations (2017) (0)
How Tolerance Shapes the Development of the HIV-1 Broadly Neutralizing Antibody 2F5 (2016) (0)
HIV Envelope vaccination elicits asparagine 332 glycan-dependent antibodies that resemble broadly neutralizing antibody precursors (2017) (0)
Brian Gaschen , Diversity Considerations in HIV-1 Vaccine Selection (2009) (0)
Blood T Cell Pools in Myasthenia Gravis Effect of Thymectomy on Human Peripheral (2001) (0)
RAB11FIP5-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures (2020) (0)
Response: Correlates of Protective Viruses Damaging to HIV Infection. (1996) (0)
Correction (1982) (0)
A brief review. Poststreptococcal glomerulonephritis. (1973) (0)
Binding of CAP206-CH12 mAb and CAP206-CH12 RUA to gp41 MPER peptide and gp41-inter protein. (2011) (0)
Moderate lossof functionof cyclic-AMP-modulated KCNQ 2 / KCNQ 3 K + channels causesepilepsy (1998) (0)
Expression of extracellular Hsp90 is a molecular signature of T cell activation, providing a means to image and target T Cell activation in autoimmune disease (2021) (0)
Publisher Correction: SARS-CoV-2 and HIV-1 — a tale of two vaccines (2021) (0)
Immunogenicity of a germline-targeting nanoparticle in knock-in mice expressing human B cell receptors of the HIV gp41 neutralizing antibody, DH511 (2022) (0)
303 Synovial lymphocyte phenotypes in the inflammatory arthritis of x-linked agammaglobulinemia (1983) (0)
Author Correction: SARS-CoV-2 and HIV-1 – A Tale of Two Vaccines (2021) (0)
Identification of CDRH3 Loops in the B Cell Receptor Repertoire that Can Be Engaged by Candidate Immunogens (2021) (0)
ImmunizationSystemic and Mucosal CTL After Nasal Cytokine Requirements for Induction of (2001) (0)
LORENZO MORETTA , ANt ) (2003) (0)
Demonstration of abnormalities in expression of thymic epithelial surface antigens in severe cellular immunodeficiency diseases. (1983) (0)
Microparticles and Apoptotic Cells Generated from Apoptotic T Cells Inhibit Human Dendritic Cell Cytokine Production (2008) (0)
Strategy for Immunogen Design CCR 5 Utilization and Suggests a New Identifies Differences in Glycosylation and C Human Immunodeficiency Virus Type 1 Acute and Chronic Infections with Subtype Comparison of Viral Env Proteins from (2013) (0)
Crystal structures in an anti-HIV antibody lineage from immunization of Rhesus macaques (2016) (0)
E-103 The pathway to HIV vaccine development (2016) (0)
A tribute to Norman L. Letvin (1949–2012) (2012) (0)
The Duke University Arthritis Center. (1991) (0)
Transcriptomic Signatures -Deficient Mice Exhibit Cytokine-Related RAB11FIP5 (2020) (0)
Immunosuppressive Therapy of Cogan??s Syndrome (1987) (0)
Characterization of Glycosylation Proﬁles of HIV-1 Transmitted/Founder Envelopes by Mass Spectrometry (cid:1) † (2011) (0)
E108 Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design (2013) (0)
Crystal structure of unliganded CH59UA, the inferred unmutated ancestor of the RV144 anti-HIV antibody lineage producing CH59 (2015) (0)
Neutralizing Antibodies Proximal External Region Broadly Epitope Overlapping Those of Membrane H Responses by an MHC-Restricted T Modulation of Nonneutralizing HIV-1 gp41 (2014) (0)
MONOCLONAL ANTIBODIES AND CANCER (1982) (0)
A conserved region at the COOH terminus of human immunodeficiency virus gpl20 envelope protein contains an immunodominant epitope (acquired immunodeficiency syndrome/synthetic peptides/retrovirus/anti-viral antibodies) (2016) (0)
975 Constitutive cytokine mRNA production in human post-natal thymus: RT-PCR analysis of cellular subsets (1996) (0)
Maternal alum-adjuvanted recombinant HIV Env vaccine does not enhance autologous virus neutralization in HIV-infected pregnant women (2019) (0)
Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates (2021) (0)
T.59. The Composition of the Primary Immunoglobulin Repertoire Influences HIV gp140 Epitope Selection (2009) (0)
New Challenges and Opportunities for HIV Vaccines and Insights from Studies of Acute HIV Infection (2015) (0)
Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates (2021) (0)
The specialized centers of research in rheumatoid arthritis. Recent progress and prospects for future advances. (1991) (0)
Cryo-EM structure of vaccine-elicited HIV-1 neutralizing antibody DH270.mu1 in complex with CH848 10.17DT Env (2019) (0)
HIV broadly neutralizing antibodies and immunological tolerance (VAC7P.988) (2014) (0)
Structure of the antibody 7968 with human complement factor H-derived peptide (2016) (0)
Identification of HIV gp41 membrane proximal epitope tetramer reactive populations of B220+ B cells and B220lo/neg basophils in gp41 peptide-immunized mice (45.3) (2007) (0)
Norman L. Letvin (1949–2012) (2012) (0)
IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells (2018) (0)
Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay (2012) (0)
T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial (2012) (0)
Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject (2012) (0)
HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers (2019) (0)
HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence (2015) (0)
HLA-E-presented peptides as novel targets for HIV-1 therapy (2019) (0)
Postnatally-transmitted HIV-1 variants are efficient at dendritic cell trans-infection and sensitive to autologous and heterologous neutralization (2012) (0)
P20-17. Evolution of multiple transmitted viruses during the early stage of HIV-1 infection (2009) (0)
Galactosylceramide the Interaction of HIV-1 gp 140 with Expose a CD 4-Inducible Epitope and Block Constant Region 1-Specific Antibodies Vaccine-Induced HIV-1 Envelope gp (2014) (0)
P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody (2009) (0)
E-102 Advances in Prophylactic HIV Vaccine Development (2014) (0)
Immune Distribution and Localization of Phosphoantigen-Speciﬁc V (cid:2) 2V (cid:3) 2 T Cells in Lymphoid and Nonlymphoid Tissues in Mycobacterium tuberculosis Infection (cid:1) (2007) (0)
Crystal structure of RV144-elicited antibody CH59 in complex with V2 peptide (2013) (0)
Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay (2012) (0)
P04-54 LB. Genetic signature analysis identifies the CD4i region of gp120 as a determinant of broadly NAb responses in HIV-1-infected individuals (2009) (0)
Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12 (2012) (0)
Functional Polymorphism of CD 45 RA 32 Mutation with a ∆ Linkage of the CCR 5 and (2000) (0)
Antibody lineages with evidence of somatic hypermutation persisting for >4 years in a South African subject with broad neutralizing activity (2012) (0)
Cryo-EM structure of HIV-1 neutralizing antibody DH270.6 in complex with CH848 10.17DT Env (2019) (0)
Recombinant Bacillus Calmette-Guérin vectors prime for strong cellular responses (2014) (0)
Apoptotic microparticles generated during acute HIV-1 infection inhibit human dendritic cells via CD44 (2012) (0)
Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C (2012) (0)
A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies (2012) (0)
Acknowledgment to Dartmouth Medical Center (1981) (0)
P04-08. Monoclonal antibodies from patient with acute HIV-1 infection (2009) (0)
P10-05. Suppression of human dendritic cell function during acute HIV infection (2009) (0)
Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants (2013) (0)
Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 (2012) (0)
Pathogenesis and Immunotherapy of Cogan’s Syndrome* (2019) (0)
Crystal Structure of DH511.4 Fab (2017) (0)
56TH FORUM IN IMMUNOLOGY - DISCUSSION (1994) (0)
Apoptotic microparticles generated during acute HIV-1 infection inhibit human dendritic cells via CD44 (2012) (0)
Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject (2012) (0)
Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12 (2012) (0)
DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies (2012) (0)
Lack of IgA envelope-reactive antibody producing cells in terminal ileum in early and chronic HIV-1 infection (2012) (0)
Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses (2012) (0)
Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein (2012) (0)
Human Immunodeﬁciency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection (cid:1) (2007) (0)
Mice Immunologic Characterization of CD 7-Deficient Jones and (1998) (0)
Synthetic hydrophilic peptiden (1989) (0)
Rapid Memory CD8 (cid:1) T-Lymphocyte Induction through Priming with Recombinant Mycobacterium smegmatis (cid:1) (2006) (0)
Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C (2012) (0)
V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site (2012) (0)
Antibody lineages with evidence of somatic hypermutation persisting for >4 years in a South African subject with broad neutralizing activity (2012) (0)
P20-08. Glycosylation: an important factor in Env diversity (2009) (0)
Molecule d'adherence (1993) (0)
A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies (2012) (0)
Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes (2012) (0)
Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses (2012) (0)
Lack of IgA envelope-reactive antibody producing cells in terminal ileum in early and chronic HIV-1 infection (2012) (0)
S021-04 OA. A large-scale analysis of immunoglobulin sequences derived from plasmablasts/plasma cells in acute HIV-1 infection subjects (2009) (0)
in leukocyte adherence and T-ceil adiva|ion (1989) (0)
How Does HIV Env Structure Informs Vaccine Design? (2020) (0)
Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived peptide bearing Ala substitutions in a helical conformation (2010) (0)
HIV-1 V 1 V 2 antibody with exceptional potency 5 6 (2015) (0)
Composition capable d'induire la production d'anticorps neutralisants très réactifs contre le vih (2010) (0)
Carbohydrate Analysis of HIV Envelope Glycoprotein (2007) (0)
Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth (2020) (0)
B cells mediated by coculture with macrophage feeder cells Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia (2012) (0)
Conversion of an Intmunogenic Human Immunodeficiency Virus ( HIV ) Envelope Synthetic Peptide to a Tolerogen in Chimpanzees by the Fusogenic Domain of HIV g l ~ l Envelope Protein (2003) (0)
Crystal Structure of DH511.2_K3 Fab in Complex with HIV-1 gp41 MPER Peptide (2017) (0)
Immunotherapy for HIV (1997) (0)
Chapter 14 – Peripheral T Cell Circulatory Kinetics and Intrathymic T Cell Differentiation in Myasthenia Gravis1 (1983) (0)
Response : HIV Quasispecies and Resampling (1996) (0)
J. Virol.-2011-Jiang-10669-81 (2012) (0)
Infection T Cell Responses during Acute HIV-1 + CD 8 and + Distinct Kinetics of Gag-Specific CD 4 and (2012) (0)
Crystal structure of the neutralizing HIV antibody 2F5 Fab fragment (recombinantly produced Fab) with 11 aa gp41 MPER-derived peptide (2010) (0)
Orbital Manifestations of Wegenerʼs Granulomatosis on Computer Assisted Tomography (1977) (0)
Monolayers and Thymic Nodules Dendritic Cells in Human Thymic Stromal Cord Blood Cells Develop into - lin - CD38 + CD34 (2017) (0)
Structural basis for breadth development in a HIV-1 neutralizing antibody (2022) (0)
HIV Never Sleeps: Evidence to Support Early Antiretroviral Treatment (2023) (0)

This paper list is powered by the following services:

Other Resources About Barton Haynes

en.wikipedia.org

What Schools Are Affiliated With Barton Haynes?

Barton Haynes is affiliated with the following schools:

Barton Haynes's Academic­Influence.com Rankings